Cellular therapies in solid tumors

Welcome to this week's podcast by VJOncology, where we delve into the emerging trends and challenges in the field of cellular therapies for oncology. Our expert panel includes Leonardo Ferreira (The Medical University of South Carolina, Charleston, SC), who discusses the groundbreaking potential and current obstacles of CAR T cells in treating solid tumors, emphasizing the innovative role of chimeric antigen receptor regulatory T cells. We also hear from Sebastian Klobuch (Netherlands Cancer Institute, Amsterdam, The Netherlands) on the advancements in TIL and TCR-modified therapies. He explores potential ways to mitigate treatment toxicities and expand the applicability of these therapies beyond melanoma. Andrew Furness (Royal Marsden Hospital, London, UK) highlights the promise of TIL therapy for melanoma, while addressing regulatory challenges. Allison Betof Warner (Stanford Cancer Center, Stanford, CA) provides insights into the evolving use of life looser in managing melanoma cases with brain metastases, alongside a specially designed pilot trial to explore treatment safety. Mina Lobbous (Case Western Reserve University, Cleveland, OH) shares updates on gene-modified gamma-delta T cells targeting glioblastoma multiforme, focusing on phase one trial outcomes and future directions for improving patient survival rates.